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Abstract: Primary care providers should be aware of two new developments in nicotine 
addiction and smoking cessation: 1) the emergence of a novel nicotine delivery system known 
as the electronic (e-) cigarette; and 2) new reports of residual environmental nicotine and other 
biopersistent toxicants found in cigarette smoke, recently described as “thirdhand smoke”. The 
purpose of this article is to provide a clinician-friendly introduction to these two emerging issues 
so that clinicians are well prepared to counsel smokers about newly recognized health concerns 
relevant to tobacco use. E-cigarettes are battery powered devices that convert nicotine into a 
vapor that can be inhaled. The World Health Organization has termed these devices electronic 
nicotine delivery systems (ENDS). The vapors from ENDS are complex mixtures of chemicals, 
not pure nicotine. It is unknown whether inhalation of the complex mixture of chemicals found 
in ENDS vapors is safe. There is no evidence that e-cigarettes are effective treatment for nicotine 
addiction. ENDS are not approved as smoking cessation devices. Primary care givers should 
anticipate being questioned by patients about the advisability of using e-cigarettes as a smok-
ing cessation device. The term thirdhand smoke first appeared in the medical literature in 2009 
when investigators introduced the term to describe residual tobacco smoke contamination that 
remains after the cigarette is extinguished. Thirdhand smoke is a hazardous exposure resulting 
from cigarette smoke residue that accumulates in cars, homes, and other indoor spaces. Tobacco-
derived toxicants can react to form potent cancer causing compounds. Exposure to thirdhand 
smoke can occur through the skin, by breathing, and by ingestion long after smoke has cleared 
from a room. Counseling patients about the hazards of thirdhand smoke may provide additional 
motivation to quit smoking.
Keywords: e-cigarette, nicotine, tobacco, thirdhand smoke, electronic nicotine delivery 
systems
Background
Tobacco use is the leading cause of preventable illness in the United States, responsible 
for more than 443,000 deaths annually.1 Since the 1964 US Surgeon General’s report 
announcing cigarette smoking to be harmful, concerns about tobacco’s deadly toll have 
become widespread and efforts to curb smoking have progressively intensified.2 Once 
thought to be a “habit” or “custom”, cigarette smoking and other forms of tobacco 
use are now widely recognized as behaviors driven by nicotine addiction. It is addic-
tion to nicotine that compels many smokers to continue to use tobacco products even 
when they appreciate its harmful effects and wish to quit.3,4
The cigarette is an effective instrument for delivering nicotine to the body. 
Burned tobacco produces vaporized nicotine which is easily entrained into the lungs. International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Within 10 to 15 seconds of puffing on a cigarette, nicotine 
is absorbed into the bloodstream of smokers and travels to 
the brain where it acts on nicotinic cholinergic receptors 
to produce a range of gratifying effects.5 The release of a 
variety of neurotransmitters results in neural activation, 
producing effects such as pleasure, appetite suppression, 
arousal, cognitive enhancement, relaxation, and reduction 
in anxiety.6–8
For most smokers, an attempt to achieve long-term 
abstinence results in failure. To improve outcomes, medica-
tions, counseling, and education have become the standard 
of care for smoking cessation treatment. Medications that 
have been shown to improve smoking cessation rates include 
nicotine replacement therapies, available as gum, patches, an 
inhaler, a nasal spray, a lozenge, and also include varenicline 
and bupropion.9–12
Public policy measures to promote smoking cessation 
and parallel measures to reduce smoking initiation have had 
major positive public health effects. Health care organiza-
tions now provide structured smoking cessation services, 
recognizing the value of this health maintenance intervention. 
Indeed, smoking cessation treatment has become a service 
that primary care providers are widely expected to deliver, 
which may be tracked as a quality measure in many health 
care organizations.13–15
Despite the expectation that primary care providers 
encourage and orchestrate the smoking cessation efforts of 
their patients, there may be persistent uncertainty regarding 
the physician’s precise role in managing the nicotine 
addicted patient. Part of this uncertainty results from the 
belief that smoking is now globally appreciated to be harmful 
and that delivering education about the hazards of smoking 
is not the best use of limited time during an office visit. The 
widespread availability of smoking cessation “quitlines” 
which provide free counseling and education by telephone in 
almost all states in the United States has also been an impor-
tant development which provides opportunities for education 
and professional counseling without direct involvement 
of a physician.16–18 Additionally, some smoking cessation 
medications (nicotine replacement drugs) are available 
over-the-counter, so that the smoker who is motivated to 
quit smoking can obtain pharmacologic treatment without 
a visit to a physician. Nevertheless, despite the availability 
of smoking cessation treatment without physician inter-
vention, primary care physician involvement in smoking 
cessation efforts remains an expectation of patients and 
other stakeholders pursuing optimal preventive health care 
and clinical outcomes.14
Two new developments in nicotine addiction and smoking 
cessation add some measure of complexity to the clinician’s 
important role in directing patients’ smoking cessation 
efforts: the emergence of a novel nicotine delivery system 
known as the electronic (e-) cigarette; and new reports of 
the hazards of residual environmental nicotine and other 
biopersistent toxicants found in cigarette smoke, recently 
described as “thirdhand smoke”.19 The remainder of the 
article provides a concise, clinician-friendly update on the 
e-cigarette and thirdhand smoke. The goal of this review is 
to provide clinicians with useful new information relevant to 
nicotine addiction, tobacco use, and smoking cessation. This 
information can be incorporated into patient counseling that 
promotes safe and effective smoking cessation strategies.
Electronic cigarettes – an untested 
nicotine delivery device
Electronic cigarettes are battery powered devices that 
convert nicotine containing liquid into a vapor that can be 
inhaled. The World Health Organization has termed these 
devices electronic nicotine delivery systems (ENDS).20 
We use the terms electronic cigarette, e-cigarette, and ENDS 
interchangeably in this review, underscoring the fact that 
clinicians may encounter any of these terms in the growing 
literature on this novel nicotine delivery system. The term 
“vaping” has emerged to describe use of the ENDS; that is, 
the inhalation of e-cigarette vapors.21,22
While multiple companies now manufacture ENDS, the 
basic design is generally similar. E-cigarettes consist of a 
plastic tube, an electronic heating element, a liquid nicotine 
cartridge, and a lithium battery and atomization chamber 
with a membrane to suspend ingredients.23 Some e-cigarettes 
contain a light emitting diode in the tip which illuminates 
when the user inhales (or “vapes”), giving the appearance 
of the burning end of a conventional cigarette. Chemicals 
introduced into the liquid vehicle produce aromas and flavors 
of tobacco, chocolate, mint, fruit, and coffee.24
ENDS were developed with the goal of mimicking the 
efficient nicotine delivery system of a conventional cigarette 
without the significant harmful effects of tobacco smoke. They 
are often marketed as the healthier version of the conventional 
cigarette. The device aerosolizes nicotine so that it is readily 
entrained into the respiratory tract and then enters the blood-
stream, resulting in a near instantaneous nicotine reward in the 
central nervous system. Propylene glycol – the chemical used 
to generate artificial “smoke” for theatrical productions – is 
added to the liquid vehicle to stimulate the appearance of using 
a “real” cigarette. The concentration of nicotine varies both International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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across different manufacturers and within the same brand. 
Cartridges vary in their nicotine content from no nicotine to 
16 to 18 mg per cartridge.20 The cost of an e-cigarette starter 
kit can range from US$40 to 120 with additional cartridges 
costing a few dollars each. After the initial investment in the 
starter kit, the recurrent daily costs (of cartridges) are some-
what more than conventional cigarettes.
Information on the pharmacology, toxicology, and 
safety of e-cigarettes is limited. Accessible information 
provides details about the presence of nicotine (including 
cotinine), tobacco specific impurities (anabasine, myosmine, 
β-nicotyrine), propylene glycol (rarely diethylene glycol), and 
tobacco specific nitrosamines (which include carcinogens) 
in commonly available brands of electronic cigarettes.24–26 
Some of the available data have been gathered from research 
sponsored by manufacturing companies of these devices.27 
No research has been conducted to test the efficacy of 
these cigarettes as smoking cessation aids.28 The marketing 
and sales of these products have not been followed by 
post-marketing studies looking at health effects, probably 
because the products are not regulated as drug delivery 
devices in most countries. Despite this knowledge gap, 
consumer interest in ENDS is growing rapidly and concerns 
about their unregulated use are intensifying.
A recent study found that the effort required (vacuum 
desired) to smoke an e-cigarette is higher than that for 
conventional cigarettes.29 This effect was accentuated after 
a few puffs resulting in nonuniform nicotine delivery, lead-
ing the authors to question ENDS as effective vehicles of 
nicotine into the patient’s lungs. Surveys have shown that 
while consumers buy electronic cigarettes for a variety of 
reasons (such as trying to quit smoking, preventing expo-
sure to smoke, being allowed to smoke in smoke free zones, 
better flavor), they remain concerned about the potential 
hazards associated with their use.30 One study has shown 
decreased desire to smoke with the use of e-cigarettes after 
overnight abstinence, when compared with a placebo or 
regular cigarettes, and an effect similar to a nicotine inhaler.31 
However, ENDS as a treatment for nicotine addiction, or as 
promoting long-term abstinence from tobacco, have not been 
formally investigated.
Claims that ENDS can aid in smoking cessation have been 
scrutinized by the US Food and Drug Administration (FDA).32 
The FDA’s position is that ENDS meet the definition of a 
drug-delivery device under the Food, Drug, and Cosmetic 
Act and should be regulated accordingly; just as nicotine 
inhalers are regulated. Thus manufacturers would be required 
to submit an application for evaluation and approval of their 
devices before they could be marketed. In September 2010, the 
FDA sent letters to 5 manufacturers of ENDS, notifying them 
that they were in violation of federal law by making claims 
that their products could help smokers quit. On December 6, 
2010, a three-judge appellate panel from the US Court of 
Appeals for the District of Columbia Circuit ruled that the 
FDA lacks authority to regulate electronic cigarettes as drugs 
or devices, thus upholding a lower court decision. The US 
Court of Appeals ruled that the FDA can only regulate ENDS 
as tobacco products. On December 20, 2010, the FDA filed 
a petition asking the US Court of Appeals in its entirety to 
conduct a hearing to review the agency’s appeal in its effort 
to regulate electronic cigarettes as devices delivering drugs. 
A decision is pending. Under the new Family Smoking 
Prevention and Tobacco Control Act passed by Congress in 
2009, the FDA has the authority to regulate tobacco products 
and therefore may have the authority to regulate ENDS, but 
not ban them, if this most recent court ruling holds. Through 
regulation, ENDS have essentially been banned in Australia, 
Canada, Singapore, and Brazil because of the lack of data 
about their safety or efficacy.20
Counseling smokers and “vapers” 
about e-cigarettes
What should the primary care provider tell the patient who 
smokes tobacco cigarettes, wants to quit, and is interested 
in e-cigarettes, or is already using e-cigarettes? What should 
clinicians tell the patient who may be using e-cigarettes in 
spaces where tobacco cigarettes are banned and who has no 
interest in quitting smoking?
Clinicians should counsel patients based on their reported 
tobacco use and their e-cigarette use behaviors and interests. 
Social, demographic, and health considerations should also 
inform the education and counseling process. We list below a 
set of quick facts and prudent talking points that clinicians can 
utilize to facilitate healthy behavioral change and reinforce 
prudent health habits:
•	 ENDS are not FDA approved as quit smoking devices.
•	 The vapors from e-cigarettes are complex mixtures of 
chemicals, not pure nicotine. Whether inhalation of the 
complex mixture of chemicals in ENDS vapors is safe is 
unknown.
•	 There is no evidence that ENDS help smokers to quit 
smoking.
•	 There is increasing resistance to the use of ENDS in public 
places and outright bans in a growing number of states.
•	 The promotion of ENDS may communicate a message 
to children and adolescents that “vaping” is harmless, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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inadvertently increasing the risk of nicotine addiction 
and tobacco use in a vulnerable population.
•	 FDA-approved treatments for smoking cessation, proven 
safe and effective, are available.
•	 Long-term abstinence from tobacco use is a goal that has 
been achieved by millions of people. Almost half of ever 
smokers alive today are former smokers.
•	 Until more information about ENDS becomes available, 
use of e-cigarettes cannot be recommended.
•	 Smoking cessation medications, conventional counseling 
strategies, including the 5 major steps to intervention 
“The 5 As”: (ask, advise, assess, assist, arrange), and 
telephone quitlines should be offered to patients who 
smoke and who wish to quit.
•	 Physicians can use information freely available on the 
web to guide their practice (http://www.surgeongeneral.
gov/tobacco/tobaqrg.htm).
•	 1-800-QUIT-NOW: The US Department of Health and 
Human Services sponsors this national telephone quit-
line. The toll-free number is a single access link to the 
national network of tobacco cessation quitlines. http://
www.smokefree.gov.
Thirdhand smoke – the hazards  
of biopersistent cigarette  
smoke residue
The term thirdhand smoke first appeared in the medical 
literature in 2009 when investigators defined it as residual 
tobacco smoke contamination that remains after the cigarette 
is extinguished.19 Anecdotal evidence suggests that nicotine – 
just one constituent of tobacco smoke – may persist in ceiling 
tiles for up to 30 years.33 A recent study found that nicotine 
persists in homes previously occupied by smokers and that 
nonsmokers who move into these homes have elevated levels 
of nicotine on their skin and in body fluids.34
Thirdhand smoke should be distinguished from second-hand 
smoke. Second-hand smoke refers to a nonsmoker’s exposure 
to the airborne products of tobacco combustion, typically in 
close temporal and physical proximity to cigarette smoking. 
In contrast, thirdhand smoke exposure may occur long after 
cigarette smoking has ceased. Particulates from cigarette 
smoke deposit on indoor surfaces and persist, resulting in 
exposures that may occur well into the future.35,36 Thirdhand 
smoke exposure is a risk of special concern to children because 
they may crawl or play on contaminated surfaces. There is no 
evidence that exposure to thirdhand smoke can be reduced or 
eliminated by increasing the rate of air exchange in an indoor 
environment through fans, open windows, or air conditioners 
after contaminants have deposited on surfaces. Parents who 
believe in the concept of thirdhand smoke exposure are more 
likely to enforce smoking bans inside the house.19
The cigarette smoke residue that persists on surfaces may 
be toxic. Nicotine, which is not a carcinogen, can deposit on 
surfaces and then react with ambient nitrous acid to produce 
tobacco specific nitrosamines (TSNAs) which include car-
cinogenic compounds. The main indoor sources of ambient 
nitrous oxide are unvented gas appliances.37,38
In an experimental model using cellulose as a model 
indoor material, a greater than 10-fold increase of surface-
bound TSNA was generated when sorbed second-hand smoke 
was exposed to nitrous acid for 3 hours.39 In this experiment, 
second-hand smoke cellulose substrates were collected in a 
room-sized 18-m3 environmental chamber with low back-
ground concentrations of airborne contaminants. Tobacco 
smoke was generated in a chamber by using a smoking 
machine. Nine cigarettes were smoked in 3 hours. A cellulose 
substrate was the medium on which nicotine from tobacco 
smoke and nitrous acid reacted to produce TSNA.
Substantial TSNA levels were also measured in the 
passenger compartment of a light duty pick-up truck in 
which the driver routinely smoked while commuting.40 In 
both models, the investigators detected a hazardous TSNA, 
1-(N-methyl-N-nitrosamino)-1-(3-pyridinyl)-4-butanal, 
which is absent in freshly emitted tobacco smoke.41 
Other potent carcinogens were also detected, including 
4-(methylnitrosamino)-1-(3-pyridinyl)-1-butanone and 
N-nitroso nornicotine.39 Investigators concluded that given 
the rapid sorption and persistence of high levels of nicotine 
on indoor surfaces, this newly identified process results in 
continuing exposure to hazardous TSNAs long after smoke is 
cleared. Dermal exposure, dust inhalation, and ingestion are 
all potential routes of exposure to these toxic compounds.
Nicotine deposits readily on surfaces and gradually 
outgases. Simulation of intense indoor smoking found 
no threshold for the adsorption of nicotine to wallboard. 
Accordingly, standard indoor domestic walls are likely to 
serve as high capacitance reservoirs for nicotine which can 
then be converted to TSNAs as described above.42,43
Although data are limited, it appears that the potential 
hazards of thirdhand smoke exposure persist long after smok-
ing has ceased. Toxic exposures might even persist for years. 
To eliminate the health risks associated with thirdhand smoke, 
it would be necessary to remove the furniture, carpets, drapes, 
curtains, and wallboards of contaminated spaces.
In June 2010, the University of California Tobacco-Related 
Disease Research Program announced a US$3.75 million International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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initiative to study the problem of thirdhand smoke. Goals 
include identifying the spectrum of toxicants, routes of 
exposure, health effects and the magnitude of exposure in 
occupational and domestic settings.44
Incorporating knowledge  
about thirdhand smoke  
into clinical practice
Thirdhand smoke is an emerging health concern. The 
magnitude of the public health threat presented by this 
exposure is not fully known. Nevertheless, general com-
ments about concerns presented by thirdhand smoke can be 
introduced into conversations with patients about the health 
hazards of smoking and their effects on bystanders who do not 
smoke. As in all conversations with patients and their family 
members about tobacco use, the message should be relevant 
and targeted. Those patients who smoke in their home and 
are concerned about the welfare of nonsmokers who live 
in or visit the home may be most responsive to discussions 
about thirdhand smoke. Currently, many smokers believe that 
“airing out” an indoor space reduces the risk for second-hand 
smoke exposure and therefore renders the space clean and 
healthy. However, the message from research on thirdhand 
smoke is clear: health hazards attributable to cigarette 
smoking persist long after the cigarette is extinguished.
Cleansers that dissolve nicotine into water must be acidic 
(eg, vinegar). Most soaps are alkaline and will not effec-
tively remove nicotine residue. While it may be possible to 
remove nicotine from smooth surfaces with an acidic clean-
ing product, removing thirdhand smoke from carpet may be 
impossible.45
We list below a set of quick facts and talking points 
that center on thirdhand smoke, which clinicians can use to 
facilitate healthy behavioral change and to reinforce prudent 
health habits:
•	 Thirdhand smoke is a hazardous exposure resulting from 
cigarette smoke residue that accumulates in cars, homes, 
and other indoor spaces.
•	 Toxicants that deposit indoors may persist indefinitely.
•	 Tobacco-derived toxicants can react to form potent 
cancer-causing compounds.
•	 Exposure to thirdhand smoke can occur through the skin, 
by breathing, and by ingestion long after smoke has been 
cleared out of a room.
•	 Children who climb on furniture, crawl and play on floors, 
may be especially susceptible to thirdhand smoke.
•	 It appears there is no safe way for nonsmokers to cohabi-
tate with smokers who smoke indoors.
Summary
The e-cigarette is a novel nicotine delivery device, which has 
some appealing features and is gaining widespread interest. 
However, a paucity of knowledge about e-cigarettes or elec-
tronic nicotine delivery systems (ENDS) and concerns about 
their safety and public health impact have raised important 
concerns about their use. ENDS are widely available, but are 
not FDA approved as quit smoking devices.
Thirdhand smoke is a newly described health hazard that 
results from cigarette smoking. Thirdhand smoke is a hazard-
ous exposure resulting from cigarette smoke residue, which 
accumulates indoors and in the passenger compartments of 
motor vehicles. Exposure to thirdhand smoke can occur long 
after airborne products of combustion (ie, smoke) have been 
cleared from a room.
Clinicians should incorporate insights about ENDS and 
thirdhand smoke into conversations with patients who smoke 
in order to facilitate healthy behavioral changes including 
smoking cessation.
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